Brief: China Biotech Services Sees HY Net Loss Attributable Of HK$81Mln
02/08/2024 11:34
Aug 2 (Reuters) - China Biotech Services Holdings Ltd
8037.HK :
* SEES HY NET LOSS ATTRIBUTABLE OF HK$81MLN
* EXPECTED RESULT FROM INCREASE OF HK$4.4 MILLION IN
RESEARCH AND
DEVELOPMENT COSTS FROM CHIMERIC ANTIGEN RECEPTOR T-CELL SEGMENT,
OTHERS
Further company coverage: 8037.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Biotech Services Holdings
See all newsBrief: China Biotech Services Enters Cooperation Agreement
Brief: China Biotech Services Says HY Revenue From Cont Ops Hk$37.23 Million
Brief: China Biotech Services Expects HY Net Profit Of Not Less Than HK$15.0 MLN
Brief: China Biotech Services Enters Master Collaboration Agreement With Stella Pharma
Brief: China Biotech Services Says BGI Songhe Advances RMB30 Million Loan To Pengbo (Hainan)